zofran 4 mg amp

zofran 4 mg amp

Description:

Zofran 4 mg amp (zofran 4 mg/2 ml ampoules for i.v/i.m injection) is a prescription antiemetic medicine containing ondansetron, a selective 5-HT3 receptor antagonist. It is used in hospitals and clinical settings to prevent and treat nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery after anesthesia. This injectable form provides rapid and reliable control of severe nausea and vomiting when oral therapy is not suitable or not tolerated.

Indications:

• Prevention of acute nausea and vomiting induced by cytotoxic chemotherapy, including highly emetogenic regimens such as cisplatin-based therapy.
• Treatment of established nausea and vomiting associated with chemotherapy when rapid control is required.
• Prevention of nausea and vomiting induced by radiotherapy, particularly total body irradiation or high-dose abdominal radiotherapy.
• Prevention and treatment of postoperative nausea and vomiting (PONV) following general or regional anesthesia.
• Use as an antiemetic adjunct in perioperative care where there is a high risk of postoperative vomiting.

Active Ingredients / Key Components:

• Ondansetron (as ondansetron hydrochloride) – 4 mg per 2 ml ampoule (2 mg/ml).
• Excipients: The full list of inactive ingredients (excipients) is not available in the provided information. Refer to the official package insert for a complete excipient list.

Dosage & Administration / How to Use:

• Zofran 4 mg amp is for intravenous (i.v) or intramuscular (i.m) use only and must be administered by a healthcare professional.
• Chemotherapy-induced nausea and vomiting (adults): Typical regimens include 8 mg i.v given immediately before chemotherapy, often followed by further doses or infusion as per protocol. Exact dosing, timing, and duration depend on the emetogenic potential of the chemotherapy and local guidelines.
• Radiotherapy-induced nausea and vomiting (adults): A single i.v dose may be given before radiotherapy; dosing schedule should follow physician instructions and official prescribing information.
• Postoperative nausea and vomiting (adults): Commonly 4 mg i.v administered slowly at induction of anesthesia or at the end of surgery, according to anesthetist’s judgment.
• Pediatric use: Dosing in children is weight-based and must strictly follow pediatric dosing guidelines and the treating physician’s instructions.
• Administer by slow intravenous injection or short infusion as recommended in the product leaflet; do not inject rapidly as a bolus unless specifically indicated.
• Do not self-inject. Use only under medical supervision in a hospital or clinic setting.
• Do not mix with other drugs in the same syringe or infusion line unless compatibility has been confirmed in the official prescribing information.

Clinical Benefits:

• Provides powerful and selective blockade of 5-HT3 receptors, effectively reducing nausea and vomiting triggered by chemotherapy, radiotherapy, and anesthesia.
• Helps patients better tolerate cancer treatment by minimizing distressing gastrointestinal side effects, supporting adherence to chemotherapy and radiotherapy schedules.
• Offers rapid onset of action via i.v/i.m route, making it suitable for acute control when oral medications are not feasible.
• Improves overall comfort and recovery in the postoperative period by reducing the incidence and severity of postoperative nausea and vomiting.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to ondansetron or any component of the formulation, or to other selective 5-HT3 receptor antagonists.
• Use with caution in patients with prolonged QT interval, congenital long QT syndrome, electrolyte disturbances (such as hypokalemia or hypomagnesemia), congestive heart failure, bradyarrhythmias, or those taking other medicines that prolong the QT interval.
• Use with caution in patients with severe hepatic impairment; dose adjustment may be required due to reduced clearance.
• Monitor for signs of serotonin syndrome when used concomitantly with other serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs, tramadol).
• May mask progressive ileus or gastric distension; use carefully in patients with recent abdominal surgery or suspected bowel obstruction.
• Consult your doctor before use if pregnant or planning pregnancy. Ondansetron should be used during pregnancy only if clearly needed and prescribed by a physician.
• If breastfeeding, consult your healthcare provider before use; a risk–benefit assessment is required.
• Inform your doctor about all medications you are taking, including antiarrhythmics, antidepressants, antipsychotics, antibiotics, and other chemotherapy agents.
• Not intended for self-medication. Hospital or clinic administration only.
• Keep out of reach of children.

Side Effects:

• Common side effects: Headache, flushing or feeling of warmth, constipation, or transient diarrhea. These are usually mild and self-limiting.
• Less common side effects: Dizziness, transient visual disturbances during rapid i.v administration, local injection site reactions, or transient liver enzyme elevations.
• Serious side effects (seek immediate medical attention): Signs of allergic reaction such as rash, itching, swelling of face or throat, severe dizziness, difficulty breathing; chest pain, irregular heartbeat, palpitations, fainting (possible QT prolongation or arrhythmia); symptoms of serotonin syndrome such as agitation, confusion, rapid heart rate, fever, muscle stiffness, or tremor.
• Report any unexpected or severe side effects to your doctor or pharmacist promptly.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children. Do not freeze. Protect ampoules from excessive heat and light. Do not use if the solution is discolored, contains particles, or if the ampoule is cracked or damaged. Do not use after the expiry date printed on the pack.

Specifications:

• Form: Sterile solution for injection in ampoules.
• Strength: 4 mg ondansetron per 2 ml ampoule (2 mg/ml).
• Route of administration: Intravenous (i.v) or intramuscular (i.m) injection.
• Pack size: 10 ampoules per pack (zofran 4 mg/2 ml 10 amp for i.v/i.m inj).

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.